Talon Therapeutics Inc (fka TLON)

[operating_line]

No choice but to wait...I suspect annual CVR payouts are possible starting in a couple of years:

Some reasons:

1. https://www.ncbi.nlm.nih.gov/pubmed/27328933
vincristine is slowly released from the liposome and delivered into the tissues more efficiently than with the standard preparation, allowing a higher dose. This increase in therapeutic index from reduced toxicity is a valuable difference between the two formulations."

"Clinicians will be informed of a new chemotherapy agent that is indicated for the treatment of adults with Philadelphia chromosome-negative acute lymphoblastic leukemia, whose disease has relapsed two or more times or whose leukemia has progressed after two or more regimens of antileukemia therapy."

2. http://www.thno.org/v06p1306.htm

3. Sales growth potential in China
http://www.prnewswire.com/news-releases/casi-pharmaceuticals-import-drug-registration-application-for-marqibo-accepted-for-review-by-cfda-300202705.html

CASI just reported expenditure on samples for the CFDA
"Our research and development expenses for the second quarter increased over the prior year due to costs associated with purchasing MARQIBO® samples required for our China import product drug application"
http://finance.yahoo.com/news/casi-pharmaceuticals-reports-second-quarter-110000670.html